Clik here to view.
Langer’s Bind Therapeutics Prices IPO at $15 Per Share
View the Slideshow Ben Fidler The biotech IPO frenzy of 2013 continued late Thursday as Bind Therapeutics, a startup co-founded by famed MIT professor Robert Langer, became the latest to …
View ArticleClik here to view.
DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris
Ben Fidler Arch Venture Partners and Polaris Partners got a windfall when they snatched deCode Genetics out of bankruptcy and flipped it to Amgen (NASDAQ: AMGN) for $415 million …
View ArticleClik here to view.
Juno Therapeutics Grabs $120M to Coax Immune System to Fight Cancer
Luke Timmerman Scientists have tried for decades to coax the body’s immune system to hunt down and kill cancer cells, much in the same way it fights viruses and bacteria. …
View ArticleClik here to view.
The Young and Proven Biotech VCs From 2012. Where Are They Now?
Luke Timmerman One of the old saws in journalism is to “follow the money” when you’re looking for a story. But sometimes you learn even more by following …
View ArticleClik here to view.
Join Xconomy for ‘What’s Hot in Cancer Immunotherapy’ on April 22
Luke Timmerman Two or three years ago, most biotech pros would have scoffed if you had predicted a revival of cancer immunotherapy. Dendreon flopped, right? Oh, how quickly things change. …
View ArticleClik here to view.
Sage Therapeutics Grabs $38M More For CNS Drugs
Ben Fidler Sage Therapeutics has just reined in another big financing round and a new group of investors to help rev up its first clinical trial—and perhaps an IPO to …
View ArticleAgios’s Blood Cancer Drug Shines in First Clinical Test
Ben Fidler When David Schenkein left Genentech to lead Agios Pharmaceuticals in 2009, part of the draw was the fact that the Cambridge, MA-based startup was positioning itself as a …
View ArticleAmid Court Fight and Trial Pauses, Juno Closes First Round at $176M
Alex Lash Supercharged Seattle startup Juno Therapeutics said Thursday it has topped off its first round of venture funding, totaling $176 million in one of the largest cash infusions a …
View ArticleClik here to view.
Sage Therapeutics Readies IPO Pitch to Develop CNS Drugs
Ben Fidler Sage Therapeutics made it pretty clear it was plotting an IPO when it added a group of public investment funds to its latest private financing round a few …
View ArticleBIO 2014: An Industry Surrounded by Insurmountable Opportunity
Standish Fleming Biotech is riding the crest of a wave of public and private financial interest unparalleled in the 36-years since the founding of Genentech. Since 2012 public markets have …
View ArticleClik here to view.
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief
Ben Fidler John Maraganore opened up an envelope in 1994 that changed his life. Inside were the results of the pivotal study of an anticoagulant drug Maraganore had created in …
View ArticleClik here to view.
Scholar Rock’s Local Approach to Immune Disease Nabs $20M
Alex Lash With a pharma partnership already in hand and big biotech names on board, the Cambridge, MA-based startup Scholar Rock today announced a $20 million Series A round of …
View ArticleClik here to view.
Sold For Parts, Accelerator Grad Allozyne Reaches End of the Line
Alex Lash With barely a whisper, Seattle biotech Allozyne has been broken up for parts, with most of its assets sold off earlier this summer to a previous licensing partner, …
View ArticleClik here to view.
Juno, Less Than a Year Old, Lines up IPO to Fund Cancer Work
Ben Fidler Few biotech startups have burst onto the scene like Juno Therapeutics. The Seattle company secured $310 million in private financing in less than a year, budding out of (Read more...)
View ArticleClik here to view.
More Biotechs Belly-Up These Days but Dendreon Still “One of a Kind”
Alex Lash Biotech companies rarely go bankrupt. Sitting where I sit, that bit of conventional wisdom comes around every so often, although it doesn’t generate quite the same buzz as (Read more...)
View Article
